LYTIR

Company · NVCT

Nuvectis Pharma, Inc.

Nasdaq's symbol directory lists NVCT on Nasdaq as “Nuvectis Pharma, Inc. - Common Stock”.

In the 12 months to Nov 8, 2026: insiders bought on 2 occasions ($1.2M); 1 filing by holders of 5% or more; 1 company report (Form 8-K, since May 26, 2026).

All insider filings at the SEC

Insider trades · SEC Form 4

Those inside the hall

Open-market purchases and sales only. Legs one person filed for one day are combined.

Who traded

  1. Mosseri Marlio Charles bought on 1 day latest Jun 30, 2026 bought $916K
  2. Ron Bentsur, Chairman & CEO bought on 1 day latest Jun 30, 2026 bought $250K
Every trade (2)
  1. BUYMosseri Marlio Charles bought Jun 30, 2026 50,000 shares filing $916K
  2. BUYRon Bentsur, Chairman & CEO bought Jun 30, 2026 12,500 shares filing $250K

Large holders · SEC Schedules 13D and 13G

Five percent and over

Anyone who comes to hold more than 5% of a company's voting shares must tell the SEC. A Schedule 13D is filed by a holder who may seek to influence the company; a 13G by one who states it is a passive investor. An amendment updates an earlier filing, and a stake reported as 0% means the holder says it has sold all, or nearly all, of its shares. Every recent 13D and 13G

  1. Soleus Private Equity Fund III, L.P. filed Aug 6, 2026 Schedule 13G passive filing 5.1%

Company reports · SEC Form 8-K

In its own words

Current reports the company filed with the SEC; most items are due within four business days of the event. Each line lists the report's items by the SEC's own titles; the filing says what happened. Reports collected since May 26, 2026; every 8-K at the SEC.

  1. Results of operations and financial condition filing Nov 4, 2026

Sources: SEC EDGAR (Forms 4, 144 and 8-K) and STOCK Act periodic transaction reports. Filings can be late, amended or wrong at the source; see methodology.